These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 15357576)

  • 1. Potent inhibitors of the hepatitis C virus NS3 protease: design and synthesis of macrocyclic substrate-based beta-strand mimics.
    Goudreau N; Brochu C; Cameron DR; Duceppe JS; Faucher AM; Ferland JM; Grand-Maître C; Poirier M; Simoneau B; Tsantrizos YS
    J Org Chem; 2004 Sep; 69(19):6185-201. PubMed ID: 15357576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The design of a potent inhibitor of the hepatitis C virus NS3 protease: BILN 2061--from the NMR tube to the clinic.
    Tsantrizos YS
    Biopolymers; 2004; 76(4):309-23. PubMed ID: 15386268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and synthesis of depeptidized macrocyclic inhibitors of hepatitis C NS3-4A protease using structure-based drug design.
    Venkatraman S; Njoroge FG; Girijavallabhan VM; Madison VS; Yao NH; Prongay AJ; Butkiewicz N; Pichardo J
    J Med Chem; 2005 Aug; 48(16):5088-91. PubMed ID: 16078825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and biological activity of macrocyclic inhibitors of hepatitis C virus (HCV) NS3 protease.
    Chen KX; Njoroge FG; Prongay A; Pichardo J; Madison V; Girijavallabhan V
    Bioorg Med Chem Lett; 2005 Oct; 15(20):4475-8. PubMed ID: 16112859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection.
    Njoroge FG; Chen KX; Shih NY; Piwinski JJ
    Acc Chem Res; 2008 Jan; 41(1):50-9. PubMed ID: 18193821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery and structure-activity relationship of P1-P3 ketoamide derived macrocyclic inhibitors of hepatitis C virus NS3 protease.
    Venkatraman S; Velazquez F; Wu W; Blackman M; Chen KX; Bogen S; Nair L; Tong X; Chase R; Hart A; Agrawal S; Pichardo J; Prongay A; Cheng KC; Girijavallabhan V; Piwinski J; Shih NY; Njoroge FG
    J Med Chem; 2009 Jan; 52(2):336-46. PubMed ID: 19102654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peptidomimetic therapeutic agents targeting the protease enzyme of the human immunodeficiency virus and hepatitis C virus.
    Tsantrizos YS
    Acc Chem Res; 2008 Oct; 41(10):1252-63. PubMed ID: 18681464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potent inhibitors of HCV-NS3 protease derived from boronic acids.
    Venkatraman S; Wu W; Prongay A; Girijavallabhan V; George Njoroge F
    Bioorg Med Chem Lett; 2009 Jan; 19(1):180-3. PubMed ID: 19022670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis, antiviral activity, and conformational studies of a P3 aza-peptide analog of a potent macrocyclic tripeptide HCV protease inhibitor.
    Randolph JT; Zhang X; Huang PP; Klein LL; Kurtz KA; Konstantinidis AK; He W; Kati WM; Kempf DJ
    Bioorg Med Chem Lett; 2008 Apr; 18(8):2745-50. PubMed ID: 18375121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel potent macrocyclic inhibitors of the hepatitis C virus NS3 protease: use of cyclopentane and cyclopentene P2-motifs.
    Bäck M; Johansson PO; Wångsell F; Thorstensson F; Kvarnström I; Ayesa S; Wähling H; Pelcman M; Jansson K; Lindström S; Wallberg H; Classon B; Rydergård C; Vrang L; Hamelink E; Hallberg A; Rosenquist S; Samuelsson B
    Bioorg Med Chem; 2007 Nov; 15(22):7184-202. PubMed ID: 17845856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis, and biological activity of m-tyrosine-based 16- and 17-membered macrocyclic inhibitors of hepatitis C virus NS3 serine protease.
    Chen KX; Njoroge FG; Pichardo J; Prongay A; Butkiewicz N; Yao N; Madison V; Girijavallabhan V
    J Med Chem; 2005 Oct; 48(20):6229-35. PubMed ID: 16190750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploring the P2 and P3 ligand binding features for hepatitis C virus NS3 protease using some 3D QSAR techniques.
    Wei HY; Lu CS; Lin TH
    J Mol Graph Model; 2008 Apr; 26(7):1131-44. PubMed ID: 18024210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Macrocyclic inhibitors of the NS3 protease as potential therapeutic agents of hepatitis C virus infection.
    Tsantrizos YS; Bolger G; Bonneau P; Cameron DR; Goudreau N; Kukolj G; LaPlante SR; Llinàs-Brunet M; Nar H; Lamarre D
    Angew Chem Int Ed Engl; 2003 Mar; 42(12):1356-60. PubMed ID: 12671967
    [No Abstract]   [Full Text] [Related]  

  • 14. Synthesis of novel potent hepatitis C virus NS3 protease inhibitors: discovery of 4-hydroxy-cyclopent-2-ene-1,2-dicarboxylic acid as a N-acyl-L-hydroxyproline bioisostere.
    Thorstensson F; Wångsell F; Kvarnström I; Vrang L; Hamelink E; Jansson K; Hallberg A; Rosenquist S; Samuelsson B
    Bioorg Med Chem; 2007 Jan; 15(2):827-38. PubMed ID: 17107807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phenylglycine as a novel P2 scaffold in hepatitis C virus NS3 protease inhibitors.
    Ortqvist P; Peterson SD; Kerblom E; Gossas T; Sabnis YA; Fransson R; Lindeberg G; Helena Danielson U; Karlén A; Sandström A
    Bioorg Med Chem; 2007 Feb; 15(3):1448-74. PubMed ID: 17113777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HCV NS3 serine protease-neutralizing single-chain antibodies isolated by a novel genetic screen.
    Gal-Tanamy M; Zemel R; Berdichevsky Y; Bachmatov L; Tur-Kaspa R; Benhar I
    J Mol Biol; 2005 Apr; 347(5):991-1003. PubMed ID: 15784258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Macrocyclic inhibitors of HCV NS3 protease.
    Venkatraman S; Njoroge FG
    Expert Opin Ther Pat; 2009 Sep; 19(9):1277-303. PubMed ID: 19563268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NMR structural characterization of peptide inhibitors bound to the Hepatitis C virus NS3 protease: design of a new P2 substituent.
    Goudreau N; Cameron DR; Bonneau P; Gorys V; Plouffe C; Poirier M; Lamarre D; Llinas-Brunet M
    J Med Chem; 2004 Jan; 47(1):123-32. PubMed ID: 14695826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pyrrolidine-5,5-trans-lactams. 1. Synthesis and incorporation into inhibitors of hepatitis C virus NS3/4A protease.
    Andrews DM; Carey SJ; Chaignot H; Coomber BA; Gray NM; Hind SL; Jones PS; Mills G; Robinson JE; Slater MJ
    Org Lett; 2002 Dec; 4(25):4475-8. PubMed ID: 12465916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resistance profiling of hepatitis C virus protease inhibitors using full-length NS3.
    Dahl G; Sandström A; Akerblom E; Danielson UH
    Antivir Ther; 2007; 12(5):733-40. PubMed ID: 17713156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.